论文部分内容阅读
目的观察依折麦布治疗肝酶轻度异常高脂血症患者的疗效及安全性。方法选择肝脏丙氨酸氨基转移酶轻度异常的高脂血症患者63例,随机分为2组。治疗组31例,给予依折麦布10mg,qd;多烯磷脂酰胆碱2片,tid,治疗共12周。对照组32例,给予阿托伐他汀20mg,qd;多烯磷脂酰胆碱2片,tid,治疗共12周。分别于入选时及治疗4、8、12周测定两组血脂、肝肾功能、血常规、血糖指标及观察2组不良反应发生情况。结果两组血脂水平均明显下降,治疗组用药前后肝肾功能、血常规无明显变化。结论依折麦布可作为肝酶轻度异常高脂血症患者的治疗选择,安全性良好。
Objective To observe the efficacy and safety of ezetimibe in the treatment of mild liver dyslipidemia patients with hyperlipidemia. Methods Sixty-three patients with mild hyperlipidemia of alanine aminotransferase in the liver were randomly divided into two groups. The treatment group of 31 cases, given ezetimibe 10mg, qd; polyene phosphatidylcholine 2, tid, for a total of 12 weeks. Control group of 32 cases, given atorvastatin 20mg, qd; polyene phosphatidylcholine 2, tid, for a total of 12 weeks. Blood lipid, liver and kidney function, blood routine, blood glucose index and the incidence of adverse reactions in the two groups were measured at the time of enrollment and 4, 8 and 12 weeks of treatment respectively. Results The blood lipid levels of both groups were significantly decreased, before and after treatment in the treatment group, liver and kidney function, blood no significant change. Conclusion Ezetimibe may be used as a treatment option in patients with mild liver dyslipidemia and is safe.